Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
49.22
Dollar change
-0.88
Percentage change
-1.76
%
IndexRUT P/E- EPS (ttm)-4.98 Insider Own14.48% Shs Outstand73.49M Perf Week-4.35%
Market Cap3.63B Forward P/E- EPS next Y-3.52 Insider Trans-0.46% Shs Float63.10M Perf Month1.25%
Income-325.10M PEG- EPS next Q-1.19 Inst Own91.87% Short Float17.71% Perf Quarter32.88%
Sales5.45M P/S666.41 EPS this Y9.02% Inst Trans12.74% Short Ratio9.41 Perf Half Y108.21%
Book/sh8.52 P/B5.78 EPS next Y24.92% ROA-47.95% Short Interest11.17M Perf Year97.12%
Cash/sh6.49 P/C7.58 EPS next 5Y- ROE-54.90% 52W Range18.00 - 53.92 Perf YTD34.85%
Dividend Est.- P/FCF- EPS past 5Y-65.72% ROI-51.42% 52W High-8.72% Beta0.83
Dividend TTM- Quick Ratio6.37 Sales past 5Y-20.00% Gross Margin40.06% 52W Low173.44% ATR (14)2.51
Dividend Ex-Date- Current Ratio6.41 EPS Y/Y TTM4.73% Oper. Margin-6297.28% RSI (14)50.05 Volatility4.09% 4.83%
Employees305 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin-5968.50% Recom1.11 Target Price67.78
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-8.01% Payout- Rel Volume1.06 Prev Close50.10
Sales Surprise527.76% EPS Surprise-16.44% Sales Q/Q- EarningsFeb 27 BMO Avg Volume1.19M Price49.22
SMA20-1.94% SMA503.71% SMA20051.28% Trades Volume1,263,169 Change-1.76%
Date Action Analyst Rating Change Price Target Change
Feb-05-24Initiated Guggenheim Buy $75
Dec-01-22Initiated BofA Securities Buy $45
Jan-19-21Reiterated H.C. Wainwright Buy $87 → $101
Oct-29-20Reiterated H.C. Wainwright Buy $58 → $73
May-05-20Initiated Barclays Overweight $48
Mar-19-20Upgrade H.C. Wainwright Neutral → Buy $40 → $60
Mar-04-20Downgrade H.C. Wainwright Buy → Neutral $40
Jan-21-20Reiterated H.C. Wainwright Buy $34 → $40
Dec-04-19Initiated H.C. Wainwright Buy
Oct-08-19Initiated Wedbush Outperform $33
Mar-04-24 06:30AM
Feb-29-24 08:30AM
Feb-27-24 07:12AM
06:30AM
Feb-22-24 07:00AM
02:42AM Loading…
Feb-07-24 02:42AM
Feb-05-24 11:26PM
Jan-31-24 07:00AM
Jan-08-24 06:30AM
Dec-21-23 07:00AM
Dec-08-23 04:05PM
Dec-05-23 12:32AM
Dec-04-23 04:13PM
Nov-29-23 07:00AM
Nov-28-23 04:41PM
04:03PM Loading…
04:03PM
Nov-27-23 06:04PM
Nov-16-23 06:30AM
Nov-02-23 07:54AM
06:30AM
Nov-01-23 06:30AM
Sep-11-23 06:30AM
Aug-02-23 06:30AM
Jun-28-23 08:29PM
Jun-07-23 07:00AM
Jun-05-23 06:30AM
May-30-23 06:30AM
May-25-23 05:05PM
May-24-23 07:00AM
May-11-23 12:14PM
06:30AM Loading…
May-03-23 06:30AM
May-02-23 07:00AM
Apr-17-23 02:32PM
02:30PM
Mar-08-23 05:05PM
Mar-01-23 07:00AM
Feb-28-23 06:30AM
Feb-27-23 06:30AM
Jan-09-23 06:30AM
Jan-03-23 07:00AM
Dec-27-22 06:30AM
Nov-22-22 07:00AM
Nov-03-22 06:30AM
Nov-01-22 11:07AM
Sep-29-22 06:30AM
Sep-10-22 10:30AM
Sep-07-22 09:56AM
09:55AM
Aug-19-22 06:30AM
Aug-04-22 06:30AM
Aug-02-22 07:00AM
Jul-15-22 06:30AM
Jul-06-22 11:38AM
Jun-13-22 09:04AM
Jun-10-22 06:30AM
Jun-09-22 07:00AM
May-27-22 09:57AM
May-26-22 05:15PM
May-25-22 12:05PM
May-24-22 08:29AM
07:59AM
07:39AM
06:30AM
May-23-22 11:24AM
May-16-22 08:30AM
May-05-22 06:30AM
Apr-19-22 06:30AM
Mar-18-22 09:15AM
Feb-24-22 06:30AM
Feb-15-22 05:03PM
Feb-08-22 01:38PM
Feb-01-22 06:30AM
Jan-12-22 01:21PM
Jan-04-22 06:30AM
Dec-27-21 09:38PM
Dec-17-21 05:38PM
Dec-15-21 08:53AM
Dec-13-21 02:24PM
11:56AM
Dec-10-21 09:24AM
06:30AM
Dec-06-21 06:30AM
Nov-29-21 06:30AM
Nov-23-21 06:30AM
Nov-10-21 09:35AM
Nov-04-21 06:30AM
Oct-27-21 06:30AM
Oct-20-21 06:45AM
06:30AM
Sep-29-21 08:47AM
Sep-07-21 12:16PM
06:30AM
Aug-30-21 06:30AM
Aug-13-21 10:24AM
Aug-04-21 06:30AM
Aug-03-21 09:00AM
06:30AM
Jul-27-21 08:00AM
Jul-20-21 07:30AM
Jul-19-21 12:08PM
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pichl DanielChief People OfficerFeb 16 '24Option Exercise27.6415,000414,60060,212Feb 20 06:56 PM
Pichl DanielChief People OfficerFeb 16 '24Sale50.1015,000751,55045,212Feb 20 06:56 PM
Ashar BhaveshChief Commercial OfficerFeb 05 '24Sale49.324,834238,43558,154Feb 05 09:24 PM
Pichl DanielChief People OfficerFeb 02 '24Option Exercise27.6416,250449,15071,393Feb 05 09:23 PM
Pichl DanielChief People OfficerFeb 02 '24Sale44.3226,1811,160,36245,212Feb 05 09:23 PM
Ashar BhaveshChief Commercial OfficerFeb 02 '24Sale44.373,222142,97662,988Feb 05 09:24 PM
Hambleton JulieDirectorJul 19 '23Sale29.312,41870,8764,648Jul 21 04:13 PM
Hambleton JulieDirectorJun 20 '23Sale26.922,40064,6037,066Jun 22 04:06 PM